Chronic respiratory diseases are among the leading causes of mortality worldwide, with the
major contributor, chronic obstructive pulmonary disease (COPD) accounting for …

Background Prospective evidence is lacking regarding incremental benefits of long-acting
dual-versus mono-bronchodilation in improving symptoms and preventing short-term …

Given the heterogeneity of chronic obstructive pulmonary disease (COPD), personalized
clinical management is key to optimizing patient outcomes. Important treatment goals …

Introduction We report the results of the first direct comparison of the once-daily fixed-dose
long-acting muscarinic antagonist/long-acting β 2-agonist (LAMA/LABA) combinations …

This real-world study evaluated the efficacy of once-daily long-acting β2-agonist
(LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) for …

Background Chronic obstructive pulmonary disease (COPD) is a progressive disease and a
composite endpoint could be an indicator of treatment effect on disease worsening. This …

Introduction Since chronic obstructive pulmonary disease (COPD) is a heterogeneous
condition, a composite endpoint of clinically important deterioration (CID) may provide a …

Background Reduced physical activity is associated with increased morbidity and mortality
in patients with COPD. Studies suggest that treatment with the long-acting muscarinic …

Background Assessments of lung function, exacerbations and health status are common
measures of chronic obstructive pulmonary disease (COPD) progression and treatment …

Abstract Background Clinically Important Deterioration (CID) is a novel composite measure
to assess treatment effect in chronic obstructive pulmonary disease (COPD). We examined …